Entrada Therapeutics (TRDA) EPS (Weighted Average and Diluted) (2020 - 2026)
Entrada Therapeutics (TRDA) recorded quarterly EPS (Weighted Average and Diluted) of -$0.95 in Q1 2026, down 1.06% quarter-over-quarter from -$0.94 in Q4 2025, and down 126.19% on a YoY basis from $3.63 in Q1 2025.
Entrada Therapeutics (TRDA) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Entrada Therapeutics' EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$0.95 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 126.19% year-over-year to -$0.95; the TTM figure through Mar 2026 stood at -$3.99 (down 639.19% YoY), while the FY2025 annual figure was -$3.47, down 306.55% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.95 for Q1 2026 at Entrada Therapeutics, down from -$0.94 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.55 in Q2 2024 to a low of -$1.06 in Q3 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.34 across 5 years, with a median of -$0.69 in 2022.
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) surged 423.81% in 2024, then slumped 2250.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.78 in 2022, then surged by 64.1% to -$0.28 in 2023, then jumped by 85.71% to -$0.04 in 2024, then plunged by 2250.0% to -$0.94 in 2025, then slipped by 1.06% to -$0.95 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.95 (Q1 2026), -$0.94 (Q4 2025), and -$1.06 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Entrada Therapeutics | 295.36 Mn | 295.36 Mn | - | -0.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.95 |
| Dec 31, 2025 | -0.94 |
| Sep 30, 2025 | -1.06 |
| Jun 30, 2025 | -1.04 |
| Mar 31, 2025 | -0.42 |
| Dec 31, 2024 | -0.04 |
| Sep 30, 2024 | -0.35 |
| Jun 30, 2024 | 1.55 |
| Mar 31, 2024 | 0.68 |
| Dec 31, 2023 | -0.28 |
| Sep 30, 2023 | 1.02 |
| Jun 30, 2023 | -0.78 |
| Mar 31, 2023 | -0.21 |
| Dec 31, 2022 | -0.78 |
| Sep 30, 2022 | -0.80 |
| Jun 30, 2022 | -0.74 |
| Mar 31, 2022 | -0.69 |
| Dec 31, 2021 | 16.02 |
| Sep 30, 2021 | -9.78 |
| Jun 30, 2021 | -7.56 |